Zhengye Biotechnology Files 20-F, Confirms 45.6M Shares Outstanding

TL;DR

**ZYBT's 20-F is a boilerplate administrative update, offering no new financial insights but confirming its 45.6 million shares outstanding.**

AI Summary

Zhengye Biotechnology Holding Ltd (ZYBT) filed its 20-F for the fiscal year ended December 31, 2024, indicating its status as an annual report. The company, incorporated in the Cayman Islands, operates in the pharmaceutical preparations industry. As of December 31, 2024, Zhengye Biotechnology had an aggregate of 45,666,376 ordinary shares outstanding, each with a par value of $0.000025. The filing confirms that ZYBT is not a well-known seasoned issuer and is required to file reports under Section 13 or 15(d) of the Securities Exchange Act of 1934. The document lists its principal executive offices at No.1 Lianmeng Road, Jilin Economic & Technical Development Zone, Jilin City, Jilin Province, China. Songlin Song is identified as the Chief Executive Officer, with contact information provided. The filing does not contain specific financial figures for revenue or net income, nor does it detail key business changes or strategic outlook, focusing primarily on administrative and corporate structure details.

Why It Matters

This 20-F filing provides crucial administrative details for Zhengye Biotechnology Holding Ltd, confirming its reporting obligations and outstanding share count of 45,666,376 ordinary shares as of December 31, 2024. For investors, this transparency on share structure is fundamental for valuation and understanding potential dilution. The confirmation of its non-well-known seasoned issuer status signals that ZYBT is still in a growth or developing phase, potentially facing different regulatory scrutiny than larger, more established pharmaceutical competitors. Employees and customers gain insight into the company's formal compliance with U.S. securities regulations, reinforcing its operational legitimacy.

Risk Assessment

Risk Level: medium — The risk level is medium because while the filing confirms regulatory compliance and basic corporate structure, it lacks specific financial performance data (revenue, net income) or detailed operational risks. Without these crucial details, investors cannot fully assess the company's financial health or future prospects, leaving significant informational gaps. The absence of a 'well-known seasoned issuer' status also suggests a potentially higher inherent risk profile compared to more established companies.

Analyst Insight

Investors should consider this 20-F as a foundational administrative update rather than a performance report. Seek out additional filings or company communications that provide detailed financial statements, operational results, and forward-looking guidance to make informed investment decisions. Do not base investment decisions solely on this administrative filing.

Key Numbers

• 45,666,376 — Ordinary Shares Outstanding (As of December 31, 2024, indicating the total number of shares in circulation.)
• $0.000025 — Par Value per Share (The nominal value assigned to each ordinary share.)
• 20241231 — Conformed Period of Report (The fiscal year-end covered by this annual report.)
• 001-42450 — Commission File Number (The SEC file number for Zhengye Biotechnology Holding Ltd.)

Key Players & Entities

• Zhengye Biotechnology Holding Ltd (company) — Registrant and filer of the 20-F
• Songlin Song (person) — Chief Executive Officer of Zhengye Biotechnology Holding Ltd
• SEC (regulator) — United States Securities and Exchange Commission
• The Nasdaq Stock Market (regulator) — Exchange where ZYBT Ordinary Shares are registered
• Cayman Islands (company) — Jurisdiction of incorporation for Zhengye Biotechnology Holding Ltd
• Jilin Economic & Technical Development Zone (company) — Location of Zhengye Biotechnology Holding Ltd's principal executive offices

FAQ

Industry Context

Zhengye Biotechnology Holding Ltd operates within the pharmaceutical preparations industry. This sector is characterized by significant research and development investment, stringent regulatory oversight, and a competitive landscape driven by innovation and market access. Companies in this industry often focus on developing, manufacturing, and marketing a range of pharmaceutical products.

Regulatory Implications

As a foreign private issuer filing a Form 20-F, Zhengye Biotechnology Holding Ltd is subject to SEC regulations regarding financial reporting and corporate governance. Compliance with these regulations is crucial for maintaining its listing on The Nasdaq Stock Market and for investor confidence.

What Investors Should Do

1. Monitor future filings for detailed financial performance.
2. Research the company's product pipeline and R&D activities.
3. Assess management's strategic direction and operational updates.

Glossary

20-F

An annual report required by the U.S. Securities and Exchange Commission (SEC) for foreign private issuers that are registered under the Securities Exchange Act of 1934. (This document is the 20-F filing for Zhengye Biotechnology Holding Ltd, providing a comprehensive overview of its corporate structure and operations for the fiscal year ended December 31, 2024.)

Ordinary Shares

The most common type of stock that represents ownership in a corporation and entitles the shareholder to voting rights and a share of profits. (Zhengye Biotechnology Holding Ltd has 45,666,376 ordinary shares outstanding as of December 31, 2024, which are traded on The Nasdaq Stock Market under the symbol ZYBT.)

Par Value

A nominal value assigned to a share of stock by the company's charter, often a very small amount, with little relation to the market value. (Each ordinary share of Zhengye Biotechnology Holding Ltd has a par value of $0.000025, indicating a very low nominal value per share.)

Section 13 or 15(d)

Sections of the Securities Exchange Act of 1934 that mandate reporting requirements for companies whose securities are traded on U.S. exchanges or that have registered securities. (Zhengye Biotechnology Holding Ltd is required to file reports under these sections, confirming its status as a reporting company with the SEC.)

Year-Over-Year Comparison

This filing covers the fiscal year ended December 31, 2024. As specific financial metrics like revenue, net income, and margin data were not detailed in this administrative-focused 20-F, a direct comparison of key financial performance indicators to the previous year is not possible based on this document alone. Future filings will be necessary to identify trends in revenue growth, profitability, and operational changes.

Filing Details

This Form 20-F (Form 20-F) was filed with the SEC on July 3, 2025 by Songlin Song regarding Zhengye Biotechnology Holding Ltd (ZYBT).

View full filing on EDGAR

View Full Filing

View this 20-F filing on SEC EDGAR